“Afrigen Biologics has earned Good Manufacturing Practice (GMP) certification from the South African Health Products Regulatory Authority (SAHPRA), validating Africa’s first fully integrated mRNA manufacturing facility. This milestone enhances Africa’s ability to produce investigational biological products for clinical trials, strengthens pandemic preparedness, and reduces reliance on imported vaccines.”
South Africa’s biotechnology industry has entered a defining era with Afrigen Biologics achieving GMP certification for its Cape Town-based mRNA manufacturing facility. This development is not only a national triumph but also a continental breakthrough, symbolizing Africa’s growing capacity to produce advanced vaccines and biologics.
Why GMP Certification Matters
- Global Standards Compliance: GMP certification ensures adherence to internationally recognized safety and quality benchmarks.
- Clinical Trial Readiness: Afrigen can now manufacture investigational biological products for Phase I and II clinical trials, a critical step toward vaccine innovation.
- Health Sovereignty: By reducing reliance on imports, South Africa strengthens its ability to respond to pandemics and supply vaccines locally.
Lessons from COVID-19
The COVID-19 pandemic exposed Africa’s vulnerability in vaccine access. Wealthy nations secured doses early, while African countries faced delays and shortages. Afrigen’s facility directly addresses this inequity, ensuring that future pandemics do not leave Africa dependent on external suppliers.
Afrigen’s Journey
- 2022–2023: Conceptualization of the mRNA Technology Transfer Programme, co-led by the World Health Organization (WHO) and the Medicines Patent Pool (MPP).
- 2024–2025: Infrastructure development, recruitment of scientists, and establishment of pilot production lines.
- 2026: GMP certification achieved, marking readiness for clinical trial material production.
Strategic Importance
Afrigen’s facility is more than a national achievement—it is a continental asset.
- Pandemic Preparedness: Rapid response capability for emerging infectious diseases.
- Regional Manufacturing Hub: A platform for vaccine production across Africa.
- Innovation Ecosystem: Collaboration between academia, government, and industry to advance biotechnology.
Voices of Leadership
Prof. Petro Terblanche, CEO of Afrigen, emphasized: “This certification is a tribute to the extraordinary commitment of our team. We are ready to support clinical trial production and contribute meaningfully to vaccine development.”
Economic and Social Impact
- Job Creation: Skilled employment opportunities for scientists, engineers, and technicians.
- Knowledge Transfer: Strengthening Africa’s scientific base through training and collaboration.
- Healthcare Equity: Ensuring vulnerable populations gain timely access to vaccines.
Global Relevance
Afrigen’s achievement resonates beyond South Africa. It demonstrates Africa’s ability to compete globally in biotechnology, challenging narratives of dependency and positioning the continent as a proactive player in global health.
Challenges Ahead
- Scaling Production: Moving from clinical trial readiness to mass production will require further investment.
- Supply Chain Stability: Ensuring raw materials and logistics remain reliable.
- Policy Support: Sustained government backing is essential to maintain momentum.
Conclusion
Afrigen’s GMP certification marks a historic milestone for Africa’s biotechnology sector. It represents resilience, innovation, and determination to secure health sovereignty. As the continent prepares for future pandemics, Afrigen’s facility stands as a beacon of progress, ensuring Africa is no longer at the mercy of external suppliers.
